Pictet Asset Management Holding SA Cuts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Pictet Asset Management Holding SA reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,540,485 shares of the biopharmaceutical company's stock after selling 78,783 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.45% of Intra-Cellular Therapies worth $128,661,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies in the third quarter worth $32,000. GAMMA Investing LLC increased its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $96,000. Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies during the third quarter valued at about $97,000. Finally, Quarry LP lifted its position in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after acquiring an additional 1,300 shares in the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of NASDAQ ITCI traded up $0.06 during trading hours on Friday, reaching $131.81. The stock had a trading volume of 1,584,630 shares, compared to its average volume of 1,391,525. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.87. The firm has a market cap of $14.04 billion, a price-to-earnings ratio of -151.50 and a beta of 0.69. The business's fifty day moving average price is $129.12 and its two-hundred day moving average price is $99.80.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITCI has been the topic of several recent analyst reports. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, StockNews.com started coverage on Intra-Cellular Therapies in a research report on Friday. They set a "hold" rating for the company. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has an average rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.